Published in Am J Public Health on May 01, 2004
Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med (1998) 7.12
Delayed access to health care: risk factors, reasons, and consequences. Ann Intern Med (1991) 4.51
Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. JAMA (1992) 4.36
Twenty years of Medicare and Medicaid: covered populations, use of benefits, and program expenditures. Health Care Financ Rev (1985) 3.78
Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery. Med Care (1999) 3.07
Comparison of uninsured and privately insured hospital patients. Condition on admission, resource use, and outcome. JAMA (1991) 2.80
The association of payer with utilization of cardiac procedures in Massachusetts. JAMA (1990) 2.74
Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol (1998) 1.51
An exploration of the complex relationship of socioecologic factors in the treatment and outcomes of acute myocardial infarction in disadvantaged populations. Health Serv Res (2001) 1.38
Socioeconomic status is an important determinant of the use of invasive procedures after acute myocardial infarction in New York State. Circulation (2000) 1.34
Coronary revascularization and cardiac catheterization in the United States: trends in racial differences. J Am Coll Cardiol (1997) 1.31
Payer status and the utilization of hospital resources in acute myocardial infarction: a report from the National Registry of Myocardial Infarction 2. Arch Intern Med (2000) 1.19
Influence of payor on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States. Participants in the National Registry of Myocardial Infarction. J Am Coll Cardiol (1998) 1.16
The marginal benefits of invasive treatments for acute myocardial infarction: does insurance coverage matter? Inquiry (2000) 1.09
Differential use of coronary revascularization and hospital mortality following acute myocardial infarction. Arch Intern Med (2003) 1.05
The process and outcome of hospital care for Medicaid versus privately insured hospital patients. Inquiry (1992) 0.94
Access to health care. Part 3: Older adults. Vital Health Stat 10 (1997) 0.92
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med (2008) 1.79
A call for higher standards of evidence for dietary guidelines. Am J Prev Med (2008) 1.69
Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol (2009) 1.67
Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med (2010) 1.63
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57
Hypertension control at physicians' offices in the United States. Am J Hypertens (2008) 1.56
Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens (2005) 1.55
Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension (2005) 1.53
Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27
Blood-pressure-related disease is a global health priority. Lancet (2008) 1.22
Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol (2005) 1.15
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med (2012) 1.13
Exercise, body mass index, caloric intake, and cardiovascular mortality. Am J Prev Med (2003) 1.10
Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08
Differential use of coronary revascularization and hospital mortality following acute myocardial infarction. Arch Intern Med (2003) 1.05
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes (2006) 1.02
Declining US stroke hospitalization since 1997: National Hospital Discharge Survey, 1988-2004. Neuroepidemiology (2008) 1.01
Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States. Am Heart J (2006) 1.00
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol (2004) 0.99
Clinical characteristics of stroke among Chinese in New York City. Ethn Dis (2004) 0.99
Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med (2002) 0.98
Is geography destiny for patients in New York with myocardial infarction? Am J Med (2003) 0.95
Sodium and cardiovascular disease. N Engl J Med (2014) 0.95
Sodium, blood pressure, and cardiovascular disease. Curr Opin Cardiol (2007) 0.94
Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology (2008) 0.93
Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens (2004) 0.92
The Cochrane review of sodium and health. Am J Hypertens (2011) 0.83
Exercise and cardiovascular outcomes by hypertensive status: NHANES I epidemiological follow-up study, 1971-1992. Am J Hypertens (2005) 0.82
Gender differences of revascularization in patients with acute myocardial infarction. Am J Cardiol (2006) 0.82
Quality of life in hypertensive patients: does it matter and should we measure it? J Hypertens (2005) 0.82
Stroke risk among Chinese immigrants in New York City. J Immigr Minor Health (2006) 0.81
Dietary Sodium and Cardiovascular Disease Risk. N Engl J Med (2016) 0.81
Blood-pressure-related disease is a global health priority. Am J Hypertens (2008) 0.80
Access to revascularization among patients with acute myocardial infarction in New York City--impact of hospital resources. J Urban Health (2006) 0.80
Podagra, uric acid, and cardiovascular disease. Circulation (2007) 0.79
Blood-pressure-related disease is a global health priority. J Hypertens (2008) 0.79
Resistant hypertension: a clinical syndrome in search of a definition. Am J Hypertens (2008) 0.78
Does blood pressure control require a Cuban-style revolution? J Hypertens (2006) 0.78
Hypertension control: improved, but not enough! Am J Hypertens (2007) 0.77
The return on INVEST. JAMA (2003) 0.76
Hypertension, silver bullets and faded dreams. J Hypertens (2004) 0.75
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. J Clin Hypertens (Greenwich) (2013) 0.75
ALLHAT and beyond. Am J Hypertens (2003) 0.75
Dietary salt and cardiovascular disease. Lancet (2011) 0.75
Hypertension control and kidney disease: some questions answered, many remain. JAMA (2002) 0.75
Estimation of death rates from pandemic influenza. Lancet (2007) 0.75
Blood pressure measures, relative and absolute risk, and international differences. J Hypertens (2002) 0.75
Hypertension in sub-Saharan Africa: what physicians can do! Am J Hypertens (2009) 0.75
Salt: data and speculation. Clin Auton Res (2002) 0.75
More about plasma renin and cardiovascular mortality. Eur Heart J (2011) 0.75
Low sodium diet after DASH: has the situation changed? Dietary Approaches to Stop Hypertension. Curr Hypertens Rep (2002) 0.75
Editor's Note. The Renin-Angiotensin System: Today and Tomorrow in Research and Clinical Practice. Am J Hypertens (2011) 0.75
Randomized clinical trials: prescriptions to be applied with caution! Am J Hypertens (2008) 0.75
Renal dysfunction predicts attenuation of ischemic heart disease mortality risk from elevated glucose among treated hypertensive patients. Am J Hypertens (2006) 0.75
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med (2012) 0.75
AJH goes to China. Am J Hypertens (2008) 0.75
Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension (2004) 0.75
Clinical problems in the management of hypertension 1) Prehypertension: should we treat? 2)The very elderly: how should we treat. J Clin Hypertens (Greenwich) (2004) 0.75
Revascularization among patients with acute myocardial infarction complicated by cardiogenic shock and impact of American College of Cardiology/American Heart Association guidelines. Am J Cardiol (2004) 0.75
The state of the journal: a report to AJH readers, reviewers, and authors. Am J Hypertens (2011) 0.75
AJH Peer Review 2014. Am J Hypertens (2015) 0.75
AJH, globalization, and the Chinese Journal of Hypertension. Am J Hypertens (2009) 0.75